Cargando…
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. We have previously described FLT3-ITD-dependent pho...
Autores principales: | Charlet, Anne, Kappenstein, Max, Keye, Philip, Kläsener, Kathrin, Endres, Cornelia, Poggio, Teresa, Gorantla, Sivahari P., Kreutmair, Stefanie, Sänger, Jana, Illert, Anna L., Miething, Cornelius, Reth, Michael, Duyster, Justus, Rummelt, Christoph, von Bubnoff, Nikolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885422/ https://www.ncbi.nlm.nih.gov/pubmed/34750506 http://dx.doi.org/10.1038/s41375-021-01462-4 |
Ejemplares similares
-
CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020) -
Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014) -
NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022) -
Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
por: Spohr, Corinna, et al.
Publicado: (2021) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)